根据您的要求，我已将提供的财报关键点按照单一主题进行分组。归类结果如下： 债务工具条款 - 2022年票据公允价值约为3.591亿美元[314] - 2022年票据转换价格为每股14.51美元[314] - 2022年票据现金利息年利率为2.25%[314] 金融衍生品交易 - 可转换票据对冲涉及23,135,435股A类普通股，执行价格为每股14.51美元[315] - 票据对冲权证交易涉及23,135,435股A类普通股，执行价格为每股18.82美元[315] 利率风险敞口与管理 - 利率立即上升1%不会对投资组合公允价值产生重大影响[310] - 公司投资主要为短期有价证券，面临利率收入敏感性风险[309] - 2022年票据和2026年票据为固定利率，对利率变化风险敞口极小[312] 现金及外汇风险 - 公司持有超出联邦存款保险限额的现金及现金等价物[311] - 公司无重大海外业务，预计不受外汇波动显著影响[316]

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2019 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-34620 IRONWOOD PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) (State or other j ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10‑K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2018 OR For the transition period from to Commission File Number 001‑34620 IRONWOOD PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation or organization) 301 Binney Street Cambridge, Massachusetts ...